Additional file 2: of PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study

Figure S1 PD-L1 expression pre and post therapy. Changes in PD-L1 expression are revealed in pre- and post-treatment RMS tissue from the same patients: RMS24, RMS18, RMS22 (A,C and E), all at diagnosis and with no prior treatment, show absence or a mild expression of PD-L1 in the immune component; RMS25, RMS19, RMS23 (B,D and F), all following several lines of treatments, mainly chemotherapy, display a moderate expression in the immune contexture outside and infiltrating the tumor burden. (PPTX 6110 kb

Multivariable model for overall survival in patients with supratentorial ependymomas (N = 145).

<p>The multivariable Cox regression model is stratified by cohort and radiotherapy.</p

Multivariable model for overall survival in patients with posterior fossa ependymomas (N = 325).

<p>The multivariable Cox regression model is stratified by cohort and radiotherapy<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0178351#t002fn001" target="_blank">^‡</a>.</p

Regression coefficients of Pediatric Intracranial Ependymomas Score (PIES).

<p>Regression coefficients of Pediatric Intracranial Ependymomas Score (PIES).</p

Multivariable model for overall survival in patients with supratentorial ependymomas with available RELA-fusion status (N = 72).

<p>The multivariable Cox regression model is stratified by cohort and radiotherapy.</p

Survival curves for supratentorial tumor patients.

<p>A) Global overall survival; B) Overall survival by cohort; C) by 1q status and D) by TNC expression.</p